High-Throughput Screening (HTS)

The Bio-Imaging Core is developing flexible and simple Cell-Based screening platforms.

The Bio-Imaging core provides an automated high-content screening scanner (INcell2000 & INcell2200, Cytiva) for High Content imaging and guidance for image and data analysis.

The core trains students to use the equipment available at the core. The Bio-Imaging core is managed by highly skilled personnel in the fields of high-content imaging, image analysis, cell-based screening, and data science. As the Bio-Imaging core is a part of the HTS unit, we can set up automated cell-based high-content assays using a state-of-the-art robotics available at the BCDD.

The Bio-Imaging core is highly involved in developing cell-based screening platforms to find therapeutic solutions for rare and ultra-rare diseases. The Bio-Imaging core is developing flexible and simple screening platforms, using patient cells or reporter cells harboring patient-specific mutations. These platforms are utilized to screen FDA approved drug libraries for drug repurposing campaigns. The high costs of the drug development process and the small patient population in most rare diseases are often not financially viable for the pharma companies.

Drug repurposing may offer an alternative route to accelerate the development of treatments for rare and ultra-rare disorders while lowering the overall research costs.